Catalyst Pharmaceuticals Secures Flagship Drug Exclusivity Until 2035 Following Legal Settlement

Coral Gables, Thursday, 7 May 2026.
By settling its patent dispute with Hetero Labs, Catalyst Pharmaceuticals secures market exclusivity for its flagship drug until 2035, guaranteeing vital long-term revenue visibility for investors.